Apertura Gene Therapy has announced its participation in a groundbreaking consortium aimed at developing gene therapies for rare childhood diseases, funded by the ARPA-H THRIVE program.

Apertura Gene Therapy has engaged in a significant collaboration with NIH institutes to develop a gene therapy targeting Niemann-Pick Disease Type C1, significantly impacting patient care.

Apertura Gene Therapy will present its innovative capsid, TfR1 CapX™, at the upcoming ASGCT meeting. The presentation will focus on advancements in gene therapy for CNS delivery.

Apertura Gene Therapy and Viralgen have partnered to manufacture TfR1 CapX, a breakthrough capsid for gene therapies aimed at central nervous system diseases.

Apertura Gene Therapy teams up with Viralgen to manufacture the innovative TfR1 CapX for treating central nervous system diseases, enhancing gene therapy prospects.

Apertura and Viralgen forge a strategic partnership to manufacture the new TfR1 CapX capsid, enhancing gene therapies for central nervous system diseases.

Apertura Gene Therapy has launched the Open Aperture program, providing free access to its TfR1 CapX capsid for academic researchers to facilitate important CNS research.

Apertura Gene Therapy has secured licensing agreements to leverage its novel AAV capsid technology, promising a breakthrough in CNS therapies.

Apertura Gene Therapy highlights its innovative AAV capsid, TfR1 CapX, at ASGCT, showcasing advancements in targeting neurological disorders through gene therapy.